- Home
- JBTM vs CRNX Comparison
JBTM vs CRNX Comparison
Compare JBTM & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JBTM
- CRNX
- Stock Information
- Founded
- JBTM 1994
- CRNX 2008
- Country
- JBTM United States
- CRNX United States
- Employees
- JBTM N/A
- CRNX N/A
- Industry
- JBTM
- CRNX Biotechnology: Pharmaceutical Preparations
- Sector
- JBTM
- CRNX Health Care
- Exchange
- JBTM Nasdaq
- CRNX Nasdaq
- Market Cap
- JBTM 6.4B
- CRNX 5.2B
- IPO Year
- JBTM N/A
- CRNX 2018
- Fundamental
- Price
- JBTM $118.92
- CRNX $37.46
- Analyst Decision
- JBTM Strong Buy
- CRNX Strong Buy
- Analyst Count
- JBTM 1
- CRNX 12
- Target Price
- JBTM $143.00
- CRNX $72.64
- AVG Volume (30 Days)
- JBTM 375.5K
- CRNX 747.4K
- Earning Date
- JBTM 02-24-2025
- CRNX 02-27-2025
- Dividend Yield
- JBTM 0.08%
- CRNX N/A
- EPS Growth
- JBTM N/A
- CRNX N/A
- EPS
- JBTM 5.38
- CRNX N/A
- Revenue
- JBTM $1,693,000,000.00
- CRNX $1,038,999.00
- Revenue This Year
- JBTM $6.46
- CRNX N/A
- Revenue Next Year
- JBTM $4.29
- CRNX $206.01
- P/E Ratio
- JBTM $26.61
- CRNX N/A
- Revenue Growth
- JBTM 1.93
- CRNX N/A
- 52 Week Low
- JBTM $82.64
- CRNX $34.07
- 52 Week High
- JBTM $133.98
- CRNX $62.53
- Technical
- Relative Strength Index (RSI)
- JBTM N/A
- CRNX 42.29
- Support Level
- JBTM N/A
- CRNX $35.10
- Resistance Level
- JBTM N/A
- CRNX $35.85
- Average True Range (ATR)
- JBTM 0.00
- CRNX 1.45
- MACD
- JBTM 0.00
- CRNX 0.47
- Stochastic Oscillator
- JBTM 0.00
- CRNX 49.78
About JBTM JBT Marel Corporation
JBT Marel Corp is a technology solutions provider to segments of the food and beverage industry. It designs, produces, and services products and systems for a broad range of end markets, generating roughly one-half of annual revenue from recurring parts, services, rebuilds, and leasing operations.
About CRNX Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.